HCB301
Solid Tumors, Hematologic Malignancies
Phase 1Active
Key Facts
About HanchorBio
A clinical-stage biotech using its FBDB™ platform to develop multi-specific fusion proteins targeting immune checkpoints for oncology and autoimmune diseases.
View full company profileTherapeutic Areas
Other Solid Tumors, Hematologic Malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| HCB303 | HanchorBio | Preclinical |